Archive | Hot Mandates RSS feed for this section

Hot Life Science Investor Mandate 1: Eastern US Angel Group Targeting Orphan Indications

19 Jul

An angel group based in the Eastern US currently has around $15 million in total assets under management, and is currently deploying capital from its third fund. The firm is looking for new opportunities in the life science space, but has no set timeline to make allocations. The group typically allocates between $250,000 and $2 million per company.

Currently, the angel group is most interested in the biotech therapeutics and medtech space, but only those that are targeting orphan indications. The group will not consider therapeutics and diagnostics that are treating any other indications besides orphan diseases due to the current difficult FDA regulatory framework.

The group is looking for pre-revenue companies within this area. However, they would consider companies in the biotech therapeutics space that have products in the preclinical stage through phase III of development, and in the medtech space the firm is looking for companies that have a product in development, or have a prototype.

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Hot Life Science Investor Mandate 2: Opportunistic PE Seeks CMO for New Allocations

19 Jul

A private equity group based in the Eastern US has around $200 million in assets, and has raised two funds. The firm is currently looking for new opportunities in the life sciences space, and although the firm has no set time frame to make allocations, they are always opportunistically looking to source new investments in the space.

The firm’s typical equity investment size ranges from $10-40 million. Currently, they are most interested in information providers as well as Biotech R&D services firms. In the information provider space, the group is seeking healthcare IT firms, and in the biotech R&D services space, the firm is looking for contract manufacturing organizations (CMOs). The firm solely invests in firms based in North America, and will consider companies headquartered in either the U.S. or Canada.

The firm is looking for companies that have $5-15 million in EBITDA, and $35-100 million in revenue, and $25-125 million in enterprise value, however EBITDA is the most important criteria in terms on the firms investment requirements. Accordingly, the firm does not invest in pre-revenue companies.

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Hot Life Science Investor Mandate 3: Venture Arm with Strong Backing Deploying Capital to Healthcare IT

19 Jul

A venture and expansion capital arm of a larger organization based in the Central US has around $300 million in total assets under management, and is currently deploying capital from its third fund, which closed at nearly $200 million. The firm is currently seeking opportunities in the life science sector, and while they have no strict timeline to make investments, they would invest in a new firm within the next 6-9 months if a compelling opportunity were identified. The firm’s equity investments range from $3-10 million, but are typically in the $8-10 million range.

Currently, this firm is most interested in the medtech, biotech diagnostics, and information providers spaces. Specifically, they are looking for healthcare IT firms within the information providers space. The firm is very opportunistic within the areas of biotech diagnostics and medtech, and would be willing to look at companies that fall within the full gamut of the medtech and diagnostics subsectors. The firm, however, will only consider US based firms within the venture and expansion capital space.

The firm is most interested in early stage companies, and is interested in pre-revenue firms. With that being said, they will look at firms that have products that are in-development, or firms that have a prototype of their product, but will not consider firms that have a device that is on the market.

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Hot Life Science Investor Mandate 3: Generalist PE Fund Interested in CROs, CMOs

11 Jul

A private equity fund located in the Central US with roughly $1 billion under management intends to make allocations in the tens of millions on a case-by-case basis in 2013. The firm is generalist and invests across sectors, but has a specific interest in life sciences & medical technologies. Within this space, the firm is opportunistic in almost every aspect, but does require that an issuer be EBITDA-positive. This means that a firm must have at least one product on the market generating revenue to be of interest. Though the firm has looked at and invested in therapeutics and medtech companies historically, a primary interest currently is service providers such as CROs and CMOs.

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Hot Life Science Investor Mandate 1: NPO Looking for Biotechs Developing Brain Disorder Therapeutics

11 Jul

A non-profit based in the Western US with nearly $50 million in assets is interested in biotech firms developing therapeutics that target brain disorders. The firm typically allocates from the hundreds of thousands into the millions per firm, and is looking to allocate to one more firm in the life science’s space for their second fund. They are especially interested in technologies that are able to deliver therapeutics across the blood brain barrier, as well as the personalized medicine space. The firm prefers funds that are in between phase I and phase II of the clinical development process, but will consider products in preclinical, phase I, and phase II development.

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Hot Life Science Investor Mandate 2: Non-Profit Targets Cancer Research, Treatment

11 Jul

A New England-based nonprofit is targeting a philanthropic fund that specifically supports scientific discoveries targeting oncology that show significant clinical potential, but which remain stuck due to insufficient funding. The organization’s primary mandate is to increase the number of cancer treatment discoveries that undergo early stage product development so that more successful treatments will make it through the pipeline.

The organization intends to write grants to emerging biotechs developing preclinical technologies. Average allocations are expected to be in the hundreds of thousands, and will be made on an opportunistic basis. Though the organization will look at opportunities across the scope of oncology therapeutics and diagnostics, companies developing molecular technologies are of particular interest.

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Hot Life Science Investor Mandate 1: European VC Interested in Wide Range of Biotech & Medtech Opportunities – June 27, 2013

26 Jun
A venture capital fund based in Europe has over €700 million in total assets under management, and has raised three funds. The firm is currently deploying assets from its third fund. The third fund’s portfolio currently consists of four companies. They are unsure of how many transactions they will execute in 2013, but aim to have ten to twelve companies in their portfolio for their third fund, and thus would invest in a firm over the next few quarters if a compelling opportunity is identified. Their typical equity check ranges from €6-10 million.

The firm is looking for companies in the biotech therapeutics & diagnostics space, and the medtech space. The fund invests in both therapeutics & diagnostics, and will consider the full gamut of subsectors and indications within the biotech therapeutics and diagnostics, as well as in the medtech space.

The VC invests in pre-revenue, early stage companies. With that being said, they are solely looking for companies that do not currently have a product on the market. In the biotech therapeutics and diagnostics space, the firm typically prefers to invest in companies one year prior to the firm starting their phase I clinical trials. In the medtech space, the firm looks for companies that have a prototype of their device.

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

← Older Entries
Newer Entries →